卵巢癌HER-2/neu基因表达的临床意义  

Clinical significance of expression of HER-2/neu pro-oncogene in ovarian carcinoma

作　　者：杨林[1] 李学汤[2] 刘丽影[2] 

机构地区：[1]华北煤炭医学院药理教研室,唐山063000 [2]中国医学科学院肿瘤医院,北京100021

出　　处：《临床肿瘤学杂志》1997年第3期27-29,共3页Chinese Clinical Oncology

摘　　要：目的:评价卵巢癌HER-2/neu表达的临床意义及对近期化疗效果的影响。方法:免疫组织化学ABC法检测49例卵巢癌HER-2/neu的表达。结果:1.卵巢癌HER-2/neu表达的阳性率为75.5％,表达阳性者的近期化疗有效率为24.3％,明显低于表达阴性者的近期化疗有效率75.0％(P<0.005)。2.HER-2/neu的表达与卵巢癌分化程度和临床分期密切相关(P<0.01,P<0.005)。3.HER-2/neu过表达的肿瘤具有远位转移的更大风险。结论:卵巢癌HER-2/neu的过表达明显影响近期化疗效果,并可能是其预后不良的肿瘤标志。Purpose:to evaluate the clinical significance and relationship between chemotherapy and expression of HER-2/neu in ovarian carcinomas. Methods:Immunohistochemical technique ABC was used to detect HER-2/neu content in 49 cases of ovarian carcinomas. Results: 1. The expression positive rates of HER-2/neu in 49 cases of ovarian carcinomas was 75. 5%. The response rate to chemotherapy of patients with positive stainings was 24. 3% and lower than that of patients with negtive stainings (75. 0%) obviously, (P<0. 005). 2. There was high correlation between expression of HER-2/neu and degree of differentiation and clinical stages in ovarian carcinomas (P<0. 01 、P<0. 005). 3. HER-2/neu pro-oncogene overexpression would led to a risk of distanct metastasis easily. Conclusion:Overexpression of HER-2/neu affects obviously the recent results of chemotherapy in o-varian carcinomas, it might be a poorer prognostic marker of the tumor.

关 键 词：卵巢癌 过表达 HER-2/NEU基因 近期 临床意义 化疗效果 有效率 肿瘤标志 免疫组织化学ABC法 预后不良 

分 类 号：R737.31[医药卫生—肿瘤] R735[医药卫生—临床医学]